Voyager Therapeutics (VYGR) Price & Analysis

Compare

1,223 Followers

VYGR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.65 - $8.28

Previous CloseN/A

Volume91.62K

Average Volume (3M)773.14K

Market Cap

$233.52M

Enterprise Value$7.06M

Total Cash (Recent Filing)$215.59M

Total Debt (Recent Filing)$40.20M

Price to Earnings (P/E)5.0

Beta1.46

Next Earnings

Nov 18, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding55,468,807

10 Day Avg. Volume854,718

30 Day Avg. Volume773,143

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.03

Enterprise Value/Revenue0.17

Enterprise Value/Gross Profit0.17

Enterprise Value/Ebitda-0.06

Forecast

1Y Price Target

$16.38

Price Target Upside285.41% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe recently-restructured company extended its cash runway into 2028, extending past multiple clinical data-related catalysts.

Strategic PositioningVoyager reiterated the sequencing strategy across its 4 wholly-owned Alzheimer’s programs, each targeting a distinct stage of disease progression, enhancing the platform and catalyzing partnerships.

Technological AdvancementThe alkaline phosphatase (ALPL) receptor-mediated non-viral NeuroShuttle showed sustained central nervous system exposure for more than 3 weeks, highlighting durability and a potential safety advantage.

Bears Say

Clinical Development RiskThere are several risks including clinical development risk, competitor risk, and capital market and dilution risk which could impact the company's future performance.

Competitor RiskThere are several risks including clinical development risk, competitor risk, and capital market and dilution risk which could impact the company's future performance.

Market RisksThere are several risks including clinical development risk, competitor risk, and capital market and dilution risk which could impact the company's future performance.

Voyager Therapeutics News

3 ‘Strong Buy’ Biotech Stocks Top Analysts Believe Have Over 300% Upside

Wall Street analysts don’t hand out “Strong Buy” ratings lightly. When they do, it usually means they’re convinced...

13d ago

CGEM

TECX

Voyager Therapeutics: Promising Alzheimer’s Portfolio and Innovative NeuroShuttle Platform Justify Buy Rating

Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

3d ago

VYGR

Buy Rating for Voyager Therapeutics: Promising NeuroShuttle Platform and Strategic Growth Potential

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VYGR stock, giving a Buy rating on...

16d ago

VYGR

Voyager Therapeutics Joins Citi’s Biopharma Conference 2025

The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). Voyager Therapeutics announced its participation in Citi’s...

16d ago

VYGR

Voyager Therapeutics: Strategic Positioning and Promising Pipeline Drive Buy Rating

Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on Voyager Therapeutics. The associated price target...

1M ago

VYGR

Voyager Therapeutics Extends Cash Runway to 2028

Voyager Therapeutics Inc. ( ($VYGR) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

VYGR

Voyager Therapeutics: Strategic Restructuring and Pipeline Progress Underpin Buy Rating

Analyst Lili (Aurélie) Nsongo of Leerink Partners maintained a Buy rating on Voyager Therapeutics, with a price target...

1M ago

VYGR

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Drive Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating today....

1M ago

VYGR

Voyager Therapeutics price target lowered to $8 from $9 at Wedbush

Wedbush lowered the firm’s price target on Voyager Therapeutics (VYGR) to $8 from $9 and keeps an Outperform...

1M ago

VYGR

Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)

Reports Q2 revenue $5.2M, consensus $9.5M. “We firmly believe Voyager’s science has the potential to drive transformative neurotherapeutics,...

1M ago

VYGR

Buy Rating for Voyager Therapeutics Driven by Promising Alzheimer’s Gene Therapy and Significant Share Price Potential

In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Voyager Therapeutics, with a...

2M ago

VYGR

Voyager Therapeutics continues expansion of its AD franchise

Voyager Therapeutics (VYGR) continued the expansion of its Alzheimer’s disease, AD, franchise with the introduction of a wholly-owned...

2M ago

VYGR

Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer?

Voyager Therapeutics Inc. (($VYGR)) announced an update on their ongoing clinical study. Voyager Therapeutics Inc. is conducting a...

2M ago

VYGR

Voyager Therapeutics demonstrates ALPL receptor-mediated BBB transport

Voyager Therapeutics (VYGR) announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase, ALPL, to...

4M ago

VYGR

VYGR FAQ

What was Voyager Therapeutics’s price range in the past 12 months?

Voyager Therapeutics lowest stock price was $2.65 and its highest was $8.28 in the past 12 months.

What is Voyager Therapeutics’s market cap?

Voyager Therapeutics’s market cap is $233.52M.

When is Voyager Therapeutics’s upcoming earnings report date?

Voyager Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 61 days.

How were Voyager Therapeutics’s earnings last quarter?

Voyager Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.526 by -$0.044.

Is Voyager Therapeutics overvalued?

According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics pay dividends?

Voyager Therapeutics does not currently pay dividends.

What is Voyager Therapeutics’s EPS estimate?

Voyager Therapeutics’s EPS estimate is -0.52.

How many shares outstanding does Voyager Therapeutics have?

Voyager Therapeutics has 55,468,807 shares outstanding.

What happened to Voyager Therapeutics’s price movement after its last earnings report?

Voyager Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.526. Following the earnings report the stock price went down -5.294%.

Which hedge fund is a major shareholder of Voyager Therapeutics?

Currently, no hedge funds are holding shares in VYGR

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.26%

Trailing 12-Months

Asset Growth

-26.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Voyager Therapeutics

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$16.38

▲(285.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.58,5.612307692307692,7.644615384615385,9.676923076923078,11.70923076923077,13.741538461538463,15.773846153846154,17.806153846153848,19.838461538461537,21.870769230769234,23.903076923076924,25.935384615384613,27.96769230769231,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.58,4.564615384615385,5.549230769230769,6.533846153846154,7.518461538461539,8.503076923076922,9.487692307692306,10.472307692307691,11.456923076923076,12.44153846153846,13.426153846153845,14.41076923076923,15.395384615384614,{"y":16.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.58,3.92,4.26,4.6,4.9399999999999995,5.279999999999999,5.62,5.96,6.3,6.64,6.9799999999999995,7.32,7.66,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.56,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >